Across TCGA pan-cancer cohorts, CHRNA5 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CHRNA5 data layer compared with 23 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CHRNA5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHRNA5 expression acts as an unfavorable survival marker, although some lineages such as ESCA and UCEC show a favorable association.
SKCM, ESCA, and UCEC are the cancer types where CHRNA5 Mutation most reproducibly stratifies survival.